BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA....
+See More2019-01-15 13:35:00 Tuesday ET
Americans continue to keep their financial New Year resolutions. First, Americans should save more money. Everyone needs a budget to ensure that key paychec
2019-08-10 21:44:00 Saturday ET
McKinsey Global Institute analyzes 315 U.S. cities and 3,000 counties in terms of how tech automation affects their workers in the next 5 to 10 years. This
2019-10-17 08:35:00 Thursday ET
The European Central Bank expects to further reduce negative interest rates with new quantitative government bond purchases. The ECB commits to further cutt
2019-03-19 12:35:00 Tuesday ET
U.S. tech titans increasingly hire PhD economists to help solve business problems. These key tech titans include Facebook, Amazon, Microsoft, Google, Apple,
2018-05-01 11:38:00 Tuesday ET
America and China play the game of chicken over trade and technology, whereas, most market observers and economic media commentators hope the Trump team to
2017-06-21 05:36:00 Wednesday ET
In his latest Berkshire Hathaway annual letter to shareholders, Warren Buffett points out that many people misunderstand his stock investment method in seve